Chemotherapy for PR Positive Breast Cancer: 87 Real Stories

87 stories match breast cancer, PR positive and chemotherapy. 81 of them mention surgery.

Cancer Stories

A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

Isolated adrenal metastasis from breast cancer: adrenalectomy and exemestane plus palbociclib

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-negative; GATA3-positive; CK7-positive; mammaglobin-positive; GCDFP-15 rare staining

Metastatic Site: right adrenal gland

After laparoscopic right adrenalectomy for isolated metastatic breast carcinoma, follow-up CT abdomen/pelvis and PET-CT showed no metastatic disease elsewhere; surveillance while on exemestane and palbociclib showed no recurrence so far.

PubMed Central
OutcomeCancer-Free / NED
Courtney, who was diagnosed with Stage III Invasive Lobular CarcinomaBreast Cancer

Stage III HR-Positive Invasive Lobular Carcinoma: Courtney's Patient Story

Patient Info: Courtney, Female, Under 40 | Stage III

Biomarkers: ER-positive; PR-positive; HER2-negative

As of June 2025, Courtney was recovering from Stage III ER-positive, PR-positive, HER2-negative ILC treatment after double mastectomy, Taxotere/Cytoxan chemotherapy, and 25 rounds of radiation, with reconstructive surgery delayed by radiation skin injury.

Lobular Breast Cancer Alliance
OutcomeCare Ongoing
Tanya, who was diagnosed with Stage III Invasive Lobular CarcinomaBreast Cancer

Stage III HR-Positive Invasive Lobular Carcinoma: Tanya's Patient Story

Patient Info: Tanya, Female, 40s | Stage III

Biomarkers: ER-positive; PR-positive; HER2-negative; grade 1

As of May 2025, Tanya was recovering from chest wall surgery, ALT flap repair, and a later skin graft after developing angiosarcoma in her radiated reconstructed breast years after Stage IIIA ILC treatment.

Lobular Breast Cancer Alliance
OutcomeSetback / Progression
Samantha, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

Stage IV HR-Positive Invasive Ductal Carcinoma: Samantha's Patient Story

Patient Info: Samantha, Female, Under 40 | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-positive

Metastatic Site: Rib; spine; pelvis

After a mixed response on the radium trial, Samantha changed to anastrozole and abemaciclib. She described the newer hormone-targeted combination as easier to tolerate and working better while remaining in ongoing treatment.

The Patient Story
OutcomeLiving With Cancer / Ongoing Therapy
Christine, who was diagnosed with Stage III Breast CancerBreast Cancer

Stage III HR-Positive Breast Cancer: Christine's Survivor Story

Patient Info: Christine, Female, Under 40 | Stage III

Biomarkers: ER-positive; PR-positive; HER2-positive

Three years after diagnosis, Christine described herself in the survivorship stage and focused on the physical and emotional effects that continued after active treatment.

The Patient Story
OutcomeSurvivorship / Surveillance
A patient, who was diagnosed with Stage IV Breast CancerBreast Cancer

Metastatic Neuroendocrine Breast Cancer With Severe Hormone Overproduction

Patient Info: Anonymized, Female, Under 40 | Stage IV

Biomarkers: ER-negative, PR focally positive, HER2-negative, PIK3CA mutation

Metastatic Site: liver, bone

Died after rapid deterioration and cardiac arrest during progressive metastatic disease.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

HER2-positive breast cancer with brain metastases: responding well to T-DXd

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-positive / HER2 IHC 3+

Metastatic Site: brain (left cerebellum, left frontal lobe, medulla)

After 14 months and 19 doses of T-DXd, brain metastases remained controlled with no symptomatic or radiological relapse and no severe T-DXd-related adverse events.

PubMed Central
OutcomeResponding Well
Katie, who was diagnosed with Stage III Invasive Lobular CarcinomaBreast Cancer

Stage III HR-Positive Invasive Lobular Carcinoma: Katie's Patient Story

Patient Info: Katie, Female, Under 40 | Stage III

Biomarkers: ER-positive; PR-positive; HER2-negative; genetic testing negative

As of February 2025, Katie was a few months beyond active treatment for Stage III ER-positive, PR-positive, HER2-negative ILC and was adjusting to maintenance therapy with Verzenio, Lupron, and Letrozole.

Lobular Breast Cancer Alliance
OutcomeCare Ongoing
Karen, who was diagnosed with Stage II Invasive Lobular CarcinomaBreast Cancer

Stage II HR-Positive Invasive Lobular Carcinoma: Karen's Survivor Story

Patient Info: Karen, Female, 40s | Stage II

Biomarkers: ER-positive; PR-positive; HER2-negative; grade 2; inherited genetic testing negative

Karen completed double mastectomy, 3 months of chemotherapy and reconstruction. She was doing well on ongoing endocrine and targeted therapy and walking 3–5 miles daily.

Lobular Breast Cancer Alliance
OutcomeCare Ongoing / Survivorship
A patient, who was diagnosed with Stage IV Breast CancerBreast Cancer

Stage IV luminal A breast cancer: liver resection and disease-free follow-up

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: luminal A; ER-positive; PgR-positive; HER2-negative

Metastatic Site: lung, liver

Disease-free after R0 hepatic segmentectomy for breast cancer liver metastasis, with May 2021 MRI showing no remaining liver nodules while she continued maintenance letrozole and goserelin.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Breast CancerBreast Cancer

Stage 4 HR-positive breast cancer: stable disease on ribociclib

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-negative

Metastatic Site: left iliac bone

Metastatic HR-positive, HER2-negative breast cancer remained without progression as of October 2024 while she continued ribociclib 400 mg plus letrozole after SBRT to a left iliac bone metastasis.

PubMed Central
OutcomeLiving With Cancer
A patient, who was diagnosed with Stage IV Breast CancerBreast Cancer

Hormone receptor-positive breast cancer metastatic to the pituitary: surgery and disease-free follow-up

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: ER 2+; PR 1+; HER2 0; GATA3 positive; CA125 elevated

Metastatic Site: pituitary

Disease-free 11 months after surgical resection of pituitary metastasis from prior hormone receptor-positive, HER2-negative breast cancer, with postoperative recovery supported by antibiotics, hormone replacement/supportive therapy, and electrolyte management.

PubMed Central
OutcomeCancer-Free / NED
Anna, who was diagnosed with Breast CancerBreast Cancer

HR-Positive Breast Cancer: Anna's Survivor Story

Patient Info: Anna, Female, Under 40

Biomarkers: ER-positive; PR-positive; HER2-positive

As of October 2024, Anna was about 7 years from diagnosis and described long-term survivorship after surgery, chemotherapy, radiation, biologic treatment, and tamoxifen-related mental-health effects.

The Patient Story
OutcomeSurvivorship / Completed Treatment
Anna, who was diagnosed with Breast CancerBreast Cancer

Anna’s Triple-Positive Breast Cancer Story

Patient Info: Anna, Female, Under 40

Biomarkers: ER-positive, PR-positive and HER2-positive

Anna completed surgery, chemotherapy and radiation and continued to navigate the effects of hormone therapy, early menopause and fertility loss.

The Patient Story
OutcomeTreatment Completed / Survivorship
A patient, who was diagnosed with Stage II Invasive Lobular CarcinomaBreast Cancer

Hormone receptor-positive invasive lobular carcinoma treated with neoadjuvant chemotherapy

Patient Info: Anonymized, Female, 50s | Stage II

Biomarkers: ER-positive; PR-positive; HER2-negative; Ki-67 20%

Three-month follow-up showed the biopsy-related pseudoaneurysm had thrombosed and regressed, clearing the way for planned neoadjuvant chemotherapy and surgery; cancer response after planned treatment was not yet available.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Stage I Invasive Ductal CarcinomaBreast Cancer

Stage 1 invasive ductal breast cancer: nipple-preserving mastectomy with reconstruction

Patient Info: Anonymized, Female, 60s | Stage I

Biomarkers: ER-positive; PR-positive; HER2-negative; Ki-67 28%

No signs of recurrence 20 months after nipple-preserving mastectomy, sentinel node biopsy, immediate reconstruction, adjuvant chemotherapy, and endocrine therapy for ER-positive, PR-positive, HER2-negative invasive ductal breast cancer.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

Stage 4 breast cancer: ongoing treatment with multi-line chemotherapy

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: Initial tumor: hormone receptor-negative; HER2 2+. 2011 recurrence: ER 10%; PR 70%; HER2 2+.

Metastatic Site: pleura/pleural effusion; lung

Metastatic breast cancer with malignant pleural effusion achieved complete response after chemotherapy and long-term endocrine therapy; PET-CT in October 2023 still showed complete response, with ongoing cardiac and bone-health management.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

Stage 4 luminal A breast cancer: tumor regression on hormone therapy

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-negative

Metastatic Site: skin, soft tissue, lungs

Metastatic Luminal A breast cancer involving skin/soft tissue and lungs showed regressing tumors and stable lung metastasis after 3 months of anti-hormone therapy plus capecitabine; longer-term control was not reported.

PubMed Central
OutcomeLiving With Cancer
Allison, who was diagnosed with Stage I Breast CancerBreast Cancer

Stage I HR-Positive Breast Cancer: Allison's Survivor Story

Patient Info: Allison Tierney, Female | Stage I

Biomarkers: ER-positive; PR-positive; HER2-positive

As of May 2024, Allison had recently completed her cancer treatment journey and reported successful hair preservation with cold capping during Taxol chemotherapy.

The Patient Story
OutcomeSurvivorship / Completed Treatment
A patient, who was diagnosed with Stage IV Invasive Lobular CarcinomaBreast Cancer

Invasive lobular breast cancer with isolated scalp metastasis: excision and endocrine therapy

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: Original breast tumor: ER-positive; PR-positive; scalp metastasis: CK7-positive; ER-positive; GCDFP-15 partially positive

Metastatic Site: scalp/skin

As of April 2024, she had no signs of recurrence in the breast or scalp and no distant metastasis after excision of the isolated scalp metastasis while continuing anastrozole.

PubMed Central
OutcomeCancer-Free / NED